SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Celera Genomics (CRA)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: gao seng who wrote (201)4/6/2000 3:47:00 PM
From: nigel bates  Read Replies (1) of 746
 
>>Even if it takes a while to get the mass spectrometers up to top speed, Celera can still make considerable progress, says Venter, as the company will be using other proteomics tools as well. A key approach, he says, will be to create antibodies to all proteins. These antibodies can then be used to fish out of a sample both targeted proteins and those they interact with.<<

Where do they get "antibodies to all proteins"? Sounds as though Celera need to contact Cambridge Antibody Technology, or someone.

nig
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News